for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr.Reddy's Laboratories Ltd

REDY.BO

Latest Trade

2,756.60INR

Change

32.80(+1.20%)

Volume

2,458

Today's Range

2,692.00

 - 

2,770.00

52 Week Range

2,065.30

 - 

2,965.20

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
2,723.80
Open
2,692.00
Volume
2,458
3M AVG Volume
11.92
Today's High
2,770.00
Today's Low
2,692.00
52 Week High
2,965.20
52 Week Low
2,065.30
Shares Out (MIL)
165.75
Market Cap (MIL)
451,640.80
Forward P/E
20.73
Dividend (Yield %)
0.73

Next Event

Q2 2020 Dr.Reddy's Laboratories Ltd Earnings Release

Latest Developments

More

Dr.Reddy's Labs Launches Of Generic Prevacid Capsules In U.S. Market

India's Dr. Reddy's Receives FDA EIR After Audit At Visakhapatnam Plant

Dr.Reddy's Laboratories Launches Bupropion Hydrochloride Extended-Release Tablets In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dr.Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Industry

Biotechnology & Drugs

Contact Info

8-2-337, Road No.3 Banjara Hills

+91.40.49002900

http://www.drreddys.com/

Executive Leadership

Satish K. Reddy

Chairman of the Board

G. V. Prasad

Co-Chairman of the Board, Chief Executive Officer, Managing Director

Saumen Chakraborty

President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE

MARC KIKUCHI

Chief Executive Officer, North America Generics

M. V. Ramana

Chief Executive Officer, Branded Markets (India and Emerging Markets)

Key Stats

2.65 mean rating - 40 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

138.7K

2018

142.8K

2019

153.9K

2020(E)

169.7K
EPS (INR)

2017

77.370

2018

56.960

2019

113.090

2020(E)

131.465
Price To Earnings (TTM)
21.05
Price To Sales (TTM)
2.90
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
13.85
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

UPDATE 1-Indian drugmaker Dr. Reddy's Q3 profit surges on strong growth in emerging markets

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets.

Indian drugmaker Dr. Reddy's Q3 profit rises 65.3 pct, beats estimates

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, driven by strong growth in emerging markets.

UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival

* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)

UPDATE 1-Indian drugmaker Dr. Reddy's Q2 profit soars past market estimates

Dr.Reddy's Laboratories posted a better-than-expected rise in second-quarter profit as higher sales in some emerging countries offset a marginal decline in business in North America, a key market for the Indian generic drugmaker.

India's Dr.Reddy's profit soars on anti-opioid drug sales in U.S.

Indian generic drugmaker Dr.Reddy's Laboratories Ltd <REDY.NS> posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.

India's Dr. Reddy's Q1 net profit rises seven-fold, beats forecast

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version of an opioid addiction drug.

UPDATE 3-British drugmaker Indivior's shares hit by copycat, new drug worries

* New drug Sublocade's initial H1 sales below Jefferies estimate

RPT-UPDATE 2-Indivior shares plummet on warning of bigger hit from copycat drug

* New drug Sublocade's initial H1 sales below Jefferies estimate

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior <INDV.L> warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

UPDATE 2-Indivior gets breather after court extends order blocking generic rival

* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)

Indian shares close slightly higher; SBI, Dr.Reddy's gain on Q4 results

Indian shares ended slightly higher on Tuesday, driven by gains in Dr. Reddy's Laboratories Ltd and State Bank of India (SBI) following their quarterly results.

UPDATE 1-India's Dr. Reddy's Q4 profit falls 19 pct on U.S. headwinds

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 19 percent drop in quarterly net profit on Tuesday, missing analysts' estimates, pulled down by headwinds in the U.S. market.

CORRECTED-India's Dr. Reddy's Q4 profit falls about 19 pct, misses estimates

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 19 percent fall in quarterly net profit, missing estimates, hurt by headwinds in the U.S. market.

BRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK

* GETS ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR API MIRFIELD PLANT, UK Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Laboratories Gets EIR From US FDA For API Cuernavaca Plant In Mexico

* SAYS GETS EIR FROM US FDA FOR API CUERNAVACA PLANT IN MEXICO Source text: https://bit.ly/2H9URmM Further company coverage:

BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate

* CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE

BRIEF-Dr.Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer

* CHIEF OPERATING OFFICER ABHIJIT MUKHERJEE TO RETIRE ON MARCH 31

BRIEF-Dr.Reddy's Labs Gets Form 483 With 4 Observations For API Hyderabad Plant Audit

* SAYS AUDIT OF API HYDERABAD PLANT IN TELENGANA BY U.S. FDA COMPLETED ON MARCH 16

BRIEF-Dr.Reddy's Laboratories Launches Levocetirizine Dihydrochloride Tablets USP, 5 Mg In U.S.

* ANNOUNCES LAUNCH OF LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS USP, 5 MG IN U.S. MARKET Source text - http://bit.ly/2FUOwea Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up